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INTRODUCTION
Platelets play an important role in thrombosis and homeostasis, but their role in neuroinflammatory and neurodegenerative diseases is yet to be determined [1] [2] [3] . Recently it was demonstrated that platelets contributed to inflammation in several conditions including infection, rheumatoid arthritis and arthrosclerosis [4] [5] [6] [7] . Since activated platelets secrete chemokines, cytokines and other proinflammatory mediators they have the capacity to initiate and regulate inflammation at the site of injury 8 . Platelet-derived factors have been shown to play a significant role in both inflammation and tissue repair, suggesting an important role of platelets in the initiation, progression and resolution of inflammation 9 . One of the proposed mechanisms of regulation of inflammation by platelets is their direct interaction with leukocytes 1 .
Platelet-leukocyte interactions have been a focus of investigations aimed at understanding the pathology of inflammatory diseases 4, 10 . Platelet-leukocyte aggregates were shown to occur in pathological processes associated with vascular abnormalities, thrombosis and inflammation 10, 11 . It was found that platelets interact with leukocytes and these interactions could modulate leukocyte function 10, 12, 13 . However, little is known about whether platelets affect the function of autoimmune CD4 T cells during neurologic diseases such as multiple sclerosis (MS).
MS is an inflammatory disease of the CNS that affects young adults and can lead to significant disability. MS and its animal model, experimental autoimmune encephalitis (EAE), involve pathogenic Th1, Th17 and recently discovered IFN-γ/IL-17double-positive CD4 T cells that recognize CNS selfantigens within myelin sheath such as myelin oligodendrocyte glycoprotein (MOG) [14] [15] [16] . MS usually begins as a relapsing remitting form (RRMS), which is characterized by unpredictable relapses followed by periods of remission. Within a 10-15 year period, many RRMS patients enter the stage of secondary progressive MS (SPMS), in which there is progressive neurologic decline without remission 17 . Current FDA-approved drugs for MS are primarily for relapsing forms of the disease. These drugs are only partially effective and many have side effects 18 . There are no treatments for MS that target platelets 19 ; however, we recently showed that FDA-approved drug Copaxone affected platelet activation 20 . Thus, the study of interactions of platelets with CD4 T cells has the potential to identify new diagnostic and therapeutic targets for MS.
It was demonstrated several decades ago that platelets may become activated during MS 21 . Platelet abnormalities such as thrombocytopenia are 25 times more common among MS patients when compared to the general population 22 . A more recent study reported that in MS patients there are increased numbers of platelet-platelet aggregates, platelet-derived microparticles and increased expression of the activation marker CD62P on platelets 23 . Taken together with reports that platelet-specific αIIbβ3 and platelets themselves are found in CNS inflammatory lesions in MS 24, 25 , these data suggest that platelets may be actively involved in MS pathogenesis both in the CNS and the periphery. Our studies, along with the study by Langer et al., demonstrated that platelets accumulate in CNS inflammatory lesions of mice with EAE, and that depletion of platelets ameliorated CNS autoimmune inflammation in rodents at early stages of the disease 25, 26 . Our previous study also identified an important link between platelet activation and degranulation (i.e. secretion of the contents of a platelet's granules, such as serotonin) and damaged neuronal tissue 26 . We found that platelets become activated by sialated brainspecific glycolipids integrated into neuronal and astroglial lipid rafts (brain lipid rafts) 26 , which become accessible to platelets due to alterations of blood brain barrier permeability during EAE and MS 27, 28 .
In the present study we investigated the functional ability of the platelets from MS patients vs. healthy control (HC) subjects to degranulate and secrete serotonin (5HT) in response to brain lipid rafts, as well as the interaction of platelets with CD4 T cells. We found that early in MS or EAE platelets exhibited distinct proinflammatory properties by secreting soluble factors 5HT, PAF, PF4 that stimulate proliferation and differentiation of pathogenic Th1, Th17, and IFN-γ/IL-17double-positive CD4 T cells. However, at more advanced stages of the disease platelets decreased 5HT content in the granules but increased the capacity to aggregate with CD4 T cells via interactions of CD62P on platelets with adhesion molecules ALCAM/CD166 on CD4 T cells resulting in downmodulation of T cell activation and suppression of CNS autoimmune inflammation.
METHODS

Subjects.
Peripheral blood samples were obtained from HC subjects and MS patients (see Supplemental Methods for details).
Platelet and mononuclear cell isolation and analysis.
For isolation and analysis of human platelets, peripheral blood samples were drawn using collecting tubes with EDTA. Whole blood and platelet rich plasma were analyzed by multicolor flow cytometry. For isolation of mononuclear cells from human subjects or mice, the Ficoll or Percoll density gradients were used according to the standard protocols (see Supplemental Methods) 10, 26, 29, 30 .
Platelet-T cell co-culture.
Human CD4 T cells were isolated from PBMCs by negative selection using a magnetic separation, and stimulated for six days with anti-CD3/CD28 antibodies. Cytokine production in culture supernatants was measured by ELISA as described 31 . Activation of human or mouse platelets with TB or ADP was performed as described (see Supplemental Methods) 26 .
Mouse models. C57BL/6 mice were purchased from Jackson Laboratories. B6.MOG-TCR transgenic mice were maintained in our colony. For CD4 T cell recall response, MOG-TCR transgenic mice were immunized with MOG/CFA 26 . EAE was induced C57BL/6 mice as described earlier (see Supplemental Methods) 26 .
Flow cytometry analysis of expression of intracellular molecules.
For intracellular detection of IL-17, IFN-, IL-4, or FoxP3, mouse or human CD4 T cells were activated with phorbol myristate acetate and ionomycin in the presence of GolgiStop for four hours. Cells were immediately stained for surface markers, fixed/permeabilized, and stained for intracellular antigens with proper antibodies directly conjugated with fluorophores. FACS analysis was performed as described previously (see Supplemental Methods)
RESULTS
Platelets from MS patients form aggregates with CD4 T cells.
In our previous study we found that platelets promote neuroinflammation and communicate with immune cells 26 . Based on this, we hypothesized that platelets could directly interact with CD4 T cells and form platelet-CD4 T cell aggregates. We tested this hypothesis and found that the average percentage of CD4 T cells that were aggregated with platelets was significantly increased (2.4-fold) in the peripheral blood of MS patients when compared with healthy control subjects (Fig. 1A ). These data demonstrate an active interaction of platelets with CD4 T cells during MS.
Platelets degranulate during MS, but fail to secrete 5HT in response to stimulation by brain lipid rafts.
In addition to increased adhesiveness to leukocytes, activated platelets have abilities to degranulate and secrete a number of proinflammatory substances, such as 5HT 26 , which are stored in their granules. It was reported that degranulating platelets produce microparticles during MS 23 and EAE 26 and become positive for Annexin V, which indicate ongoing processes of platelet activation and vesiculation 35 . We found that platelets from MS patients significantly increased (~2-fold increase for mean level) the Annexin V staining (Fig. 1B) . In addition, we confirmed a reported increase 23 in the proportion of platelet-derived microparticles in the peripheral blood of MS patients (Online Fig. I ), indicating platelet degranulation during MS. We also found 2.8-fold decrease in 5HT level in the platelets of MS patients when compared to that of HC (Fig. 1C) , indicating possible release of 5HT from platelet's granules. Further analysis showed a 2-fold higher background level of 5HT in platelet-free plasma of MS patients vs. HC (Fig. 1D , left panel; Background Serotonin Release). Platelets are the main and the only source of serotonin in the peripheral blood, while 5HT originates from enterochromaffin cells in the gut and then is taken up by platelets 36 . Therefore 2.8-fold decrease in 5HT content in MS platelets, a 2-fold increase in the level of 5HT in platelet-free plasma, a 2-fold increase in Annexin V expression on circulating platelets, and an increase in the number of platelet-derived microparticles in the peripheral blood of MS patients indicate an active process of platelet degranulation during MS.
In our previous study we showed that brain lipid rafts (LR) play a role in the activation of mouse and human platelets and the initiation of neuroinflammation in the EAE model 26 . We thus compared the level of 5HT release in response to LR from platelets of MS patients vs. HC ( Fig. 1D ; right panel; Induced Serotonin Release). We found that platelets from HC released serotonin in response to LR leading to 3.8-fold higher 5HT level in platelet-free plasma when compared to background levels of 5HT in plasma ( Fig. 1D ; HC and HC-LR). At the same time, platelets from MS patients did not have increased levels of 5HT release above background level in response to LR ( Fig. 1D ; MS and MS-LR). Thus in contrast to platelets from HC, platelets from MS patients failed to secrete 5HT upon stimulation with LR.
Unresponsiveness of platelets from MS patients to LR could be due to desensitization of platelet signaling pathways or to exhaustion or depletion of substances stored in platelet granules (such as 5HT) due to chronic activation. We found that platelets from MS patients, which secreted lower amounts of 5HT in response to stimulation with LR, had a comparable level of activation of downstream signal pathways as measured by Ca 2+ influx ( Fig. 1E ; HC and MS), demonstrating that the activation of signaling pathways in platelets from MS patients was unaltered. At the same time we found that 5HT was substantially decreased in platelets from MS patients (Fig.1C) , which confirms previously reported study 37 . Thus, all of these results support the hypothesis that platelets become exhausted during MS in their ability to secrete 5HT, which will be further addressed. In summary, platelets from MS patients formed aggregates with CD4 T cells, demonstrated signs of degranulation (Annexin V staining, formation of platelet-derived microparticles, decrease in 5HT content in platelets), and failed to release 5HT in response to LR.
Platelets become Annexin V-positive during early stages of MS, but form platelet-CD4 T cell aggregates during advanced stages of the disease.
Following the results showing broad distributions of percentages of platelet-CD4 T cell aggregates in the peripheral blood of MS patients (Fig.1A) , we decided to compare HC with three groups of MS patients with different expanded disability status scale (EDSS) levels (these serve as an indicator of the progression of the disease) for platelet-CD4 T cell aggregate formation. We also investigated the level of Annexin V staining in these three groups of MS patients. The group of MS patients with more advanced stages of the disease (with the highest EDSS level range of 3-6.5) had the highest level of platelet-CD4 T cell aggregates when compared to HC or two other groups of MS patients with lower EDSS levels (Fig. 1F) . On the other hand, we found that the highest level of Annexin V staining was observed in two groups of MS patients with early stages of the disease, with no or mild neurological symptoms (EDSS level ranges of 0-1 and 1.5-2.5, respectively), when compared to HC or the third group of patients with the highest EDSS level (range of 3-6.5) (Fig. 1G) . Thus, platelets become Annexin Vpositive in MS patients with no or mild neurological symptoms while the formation of platelet-CD4 T cell aggregates was associated with progression of neurological clinical symptoms during more advanced stages of the disease.
Platelets from MS patients are exhausted in their ability to release contents from both dense and alphagranules in response to activating stimuli.
From our previous results, not only dense granule component 5HT was released during stimulation of mouse and human platelets with LR but also releases of alpha granule components PF4 and IL-1α were observed 26 , as well as upregulation of CD62P (not shown). The result of action of LR on many features of platelet activation and degranulation was comparable to that of thrombin (TB) 26 . Thus we hypothesized that we observe general phenomena of exhaustion of platelets from MS patients, which is characterized by inability to secrete 5HT and PF4 (i.e. both dense and alpha granule components) in response to various stimuli such as LR, TB or ADP. To test this, we analysed three HC individuals and three MS patients with impaired release of 5HT induced by LR and investigated PF4 release from the same individuals during the same experiment. Similarly to our previous study 26 , we found that platelets from HC released both 5HT and PF4. The releases of PF4 from HC platelets were less potent when compared to 5HT, but were observed for HC platelets stimulated with LR or ADP (Online Table II ). At the same time platelets from MS patients failed to release both 5HT and PF4 in response to LR or ADP (Online Table II ). Thus we found that platelets from MS patients failed to release products from both dense and alpha-granules upon stimulation with LR.
Normal platelets skew the differentiation of CD4 T cells towards Th1 and Th17 phenotypes.
To investigate whether platelets affect the function of CD4 T cells, we performed co-culture experiments of CD4 T cells with platelets isolated from the same healthy subjects. We found that at optimal physiologic CD4 T cell-platelet ratio (1:15), platelets increased the percentages of IFN- ( Fig.  2A) and IL-17 ( Fig. 2B) producing CD4 T cells. Co-culture of CD4 T cells with platelets did not result in an increase of Tregs or Th2 cells: it was trend for decreased percentages of Tregs (Fig. 2C ) and Th2 cells (Fig. 2D) . When we investigated the production of Th2-(IL-4), Th1-(IFN-, GM-CSF), and Th17-(IL-17, GM-CSF) associated cytokines in culture supernatants by ELISA, we found that co-culture of CD4 T cells with platelets resulted in up-regulation of Th1-and Th17-associated cytokines IFN-, IL-17 and GM-CSF but not Th2-cytokine IL-4 ( Fig. 2E-H) . . Thus co-culture of human platelets with CD4 T cells promoted differentiation of human CD4 T cells towards Th1 and Th17 phenotypes.
Activated platelets from MS patients fail to differentiate CD4 T cells towards Th1 and Th17 phenotypes.
We next compared the ability of platelets isolated from MS patients or HC to skew the differentiation of CD4 T cells towards Th1 and Th17 phenotypes. We found that MS platelets had an impaired ability to skew the differentiation of CD4 T cells towards Th1 (Fig. 3A, Platelets) , Th17 (Fig.  3B, Platelets) , and IFN-γ/IL-17double-positive CD4 T cells (Fig. 3C , Platelets) when compared to HC platelets. Moreover, platelets from MS patients had impaired ability to stimulate proliferation of CD4 T cells and resulted in decrease in absolute numbers of Th1 and T17 cells in co-cultures (not shown). In addition, CD4 T cells from MS patients were less able to become differentiated towards Th1, Th17, and IFN-γ/IL-17 double-positive CD4 T cells when compared to HC (Fig. 3A-C, CD4 ).
In keeping with the observation that platelets from MS patients were more activated ex vivo compared to HC (Fig. 1A,B) , we hypothesized that chronic in vivo activation and exhaustion of secretary granules lead to a decrease in the ability of platelets from MS patients to activate CD4 T cells in vitro (Fig. 3A-C) . To test this hypothesis, we activated in vitro platelets from HC with classic platelet activating agonists TB or ADP (or incubated platelets with buffer as a control), washed them, and added them to co-cultures. It was found that pre-activation of HC platelets with TB, or ADP, substantially reduced ability of platelets to enhance the production of IFN- (Fig. 3D ), IL-17 ( Fig. 3E ), or both IFN-γ and IL-17 ( Fig. 3F ) when co-cultured with CD4 T cells. These results suggest that activated platelets lose their ability to stimulate Th1/Th17 differentiation.
Taken together, these data suggest that platelets from MS patients are much less potent in skewing differentiation of CD4 T cells towards Th1 and Th17, which correlates with their activation and decrease in ability to secrete proinflammatory factors such as 5HT (Fig 1C) .
Platelet-derived soluble factors 5HT, PF4, and PAF contribute to Th1/Th17 differentiation.
It was reported that platelet-derived soluble factors 5HT, PF4 and PAF could contribute to T cell proliferation and Th1/Th17 differentiation 6, 12, [38] [39] [40] [41] . By using anti-5HT and anti-PF4 antibodies, and PAFR inhibitor, we found that platelet-derived 5HT contributed to increased proliferation of CD4 T cells and differentiation towards Th1, while PF4 and PAF contributed to Th17 differentiation (Online Fig. II ).
Activated platelets have high capacity to form platelet-CD4 T cell aggregates, which leads to decrease in CD4 T cell proliferation and IFN- production.
In the previous experiments we found that platelets became activated and the levels of platelet-CD4 T cell aggregates were increased during MS (Fig. 1A,B) . Therefore we investigated the role of activated vs. not activated platelets in the formation of platelet-CD4 T cell aggregates and the influence of aggregation of CD4 T cell by platelets on T cell activation, proliferation and differentiation. We hypothesized that activated platelets had a higher capacity to form aggregates with T cells and downmodulate T cell activation in these aggregates. Two following findings supported our hypothesis. First, we found that human CD4 T cells that were aggregated with platelets had ~10-fold lower levels of proliferation and ~3-fold lower levels of IFN-γ production, when compared to CD4 T cells that were not aggregated with platelets in the same co-cultures (Online Fig. IIIA) . Second, we observed that human TBactivated platelets had higher capacity to do both downmodulate CD4 T cell proliferation and IFN-γ production in platelet-T cell aggregates (Online Fig. IIIB,C ) and form these platelet-CD4 T cell aggregates (Online Fig. IIID,E) . Thus, the formation of aggregates of human CD4 T cells with activated platelets resulted in downmodulation of T cell proliferation and differentiation.
Platelets promote proliferation and differentiation of MOG-specific autoimmune T cells towards Th1 and Th17 in vivo.
To confirm our in vitro results with human CD4 T cells, we used MOG-TCR transgenic mice where ~90% of T cells recognize myelin self-antigen MOG. Previously we found that depletion of platelets substantially ameliorated EAE induced by active immunization of mice with MOG 26 . In this study we investigated the role of platelets in activation of MOG-specific T cells in vivo. We immunized MOG-TCR transgenic mice with MOG 35-55 peptide and found that depletion of platelets in vivo resulted in decreased proliferation of myelin-specific CD4 T cells as indicated by BrdU and 3 H-thymidin incorporation assays (Fig. 4A,B) , and decrease in the percentages and absolute numbers of and IFN-and IL-17 producing CD4 T cells (Fig. 4C-E) . Furthermore, depletion of platelets increased apoptosis of myelin-specific CD4 T cells (Fig. 4F) , suggesting that platelets also provide survival factors to pathogenic T cells during their activation. Thus we found that platelets contributed to the priming and activation of myelin-specific T cells in vivo and their differentiation towards Th1 and Th17.
Platelets become Annexin V positive early in EAE and form platelet-CD4 T cell aggregates during advanced stages of the disease.
We further investigated Annexin V expression on platelets during EAE following our findings in MS (Fig. 1B) . Similar to MS patients, we found that platelets from mice with EAE had 2.1-fold increase in the level of Annexin V staining (Fig. 5A ). This was observed during the preclinical stages of the disease (Fig. 5A , day 5 and day 9). Starting from day 14 (EAE onset) the level of Annexin V staining returned to control levels of unmanipulated healthy animals ( Fig.5A , day 14 and day 20) , indicating that the process of platelet activation/degranulation was transient and occurred during the early stages of EAE. Since it is known that platelet activation/degranulation was accompanied by release of platelets' granule constituents, we investigated the level of 5HT in the mouse platelets activated in vitro with TB, or ADP or investigated 5HT level in platelets during EAE. We found that TB-and ADP-activated platelets had significantly reduced 5HT content (Fig. 5B ). We also found that the level of 5HT in platelets was decreased during EAE as early as d5 post-immunization. Serotonin content in the platelets reached its minimum level on d9, after which it was gradually increased on d14, d20, and d30, but still stayed below 5HT level in platelets of healthy mice ( Fig 5C) . In contrast to the level of Annexin V staining, the relative level of platelet-CD4 T cell aggregates began to increase on day 14 (disease onset) and was increased 2.3-fold during the peak of disease on d20 (Fig. 5D ). Thus platelet activation/degranulation occurred in early preclinical stages of the disease, while formation of platelet-CD4 T cell aggregates occurred during the peak of the disease.
CD62P expression on activated platelets plays an important role in the formation of platelet-CD4 T cell aggregates and downmodulation of T cell activation.
Based on our previous results (Online Fig. III) , we proposed that the ability of platelets to form aggregates with CD4 T cells imply that the platelets are activated and express CD62P. We tested this hypothesis in the mouse model and found that activated mouse platelets had high capacity to bind to CD4 T cells via CD62P-ALCAM contact interactions and interfere with the delivery of co-stimulatory signals from antigen presenting cells to T cells leading to a decreased level of CD4 T cell activation (Online Fig.  IV ). Contact interactions of activated mouse platelets with CD4 T cells were also evident in scanning electron microscopy images (Online Fig. V ). Thus activated mouse platelets preferentially formed platelet-CD4 T cell aggregates and decreased CD4 T cell activation in these aggregates.
Formation of platelet-CD4 T cell aggregates resulted in amelioration of EAE.
In the previous in vitro experiments we found that adhesion of activated platelets to CD4 T cells resulted in decreased level of T cell activation (Online Figs. III-V). In addition, we demonstrated that anti-CD62P antibodies significantly decreased the formation of platelet-CD4 T cell aggregates in vitro (Online Fig. IV) . It was reported that CD62P, which is expressed on activated platelets, played an important role in the formation of platelet-leukocyte aggregates including CD4 T cells in humans and mice [42] [43] [44] [45] [46] . Based on this, we decided to investigate the role of platelet-CD4 T cell aggregates in vivo in the EAE model. We further investigated the level of platelet-CD4 aggregates starting from the peak of the disease at d20 when we initially observed an increase in the level of platelet-CD4 T cell aggregates (Fig. 5D ). We found that the percentages of platelet-CD4 T cell aggregates in the peripheral blood reached the highest level on day 35, when mice spontaneously recovered from the disease ( Fig. 6A,B ; CS). When we isolated mononuclear cells from the spleen using the Ficoll gradient, we also found that platelets formed aggregates with CD4 T cells in the spleen during EAE with kinetics similar to that of peripheral blood ( Fig. 6C ; CS). When we injected anti-CD62P antibodies i.v. starting from d20 as indicated by arrows on Fig.6A , we found that the levels of platelet-CD4 T cell aggregates were substantially decreased by day 35 in peripheral blood and spleen ( Fig. 6B ,C; Anti-CD62P) while EAE was substantially exacerbated when compared with control group of mice (Fig. 6A ). As an alternative method to decrease the level of CD4-T cell aggregates we performed the depletion of platelets with anti-TS, as we did in Fig. 4 . Administration of anti-TS during EAE starting from d20 also resulted in a decrease in platelet-CD4 aggregates in peripheral blood and spleen, and the effect was similar to that of anti-CD62P antibodies ( Fig. 6B,C ; Anti-TS). In addition to exacerbation of EAE (Fig. 6A) , administration of anti-CD62P antibodies resulted in ~2-fold and ~4-fold increases in the level of proliferation of CD4 T cells in the spleen and CNS on d35, respectively ( Fig. 6D-G ). Thus we found that formation of platelet-CD4 T cell aggregates in vivo decreased the level of proliferation of CD4 T cells in the CNS and periphery and contributed to recovery from EAE.
Depletion of platelets during late stages of EAE exacerbates the disease.
Since formation of platelet-CD4 T cell aggregates resulted in milder EAE disease symptoms (Fig.  6A ), and depletion of platelets decreased the percentage of platelet-CD4 T cell aggregates in peripheral blood and spleen (Fig. 6B,C) , we further investigated the role of platelets during the late stages of EAE by performing platelet depletion. We have previously found that during preclinical stages of the disease, the depletion of platelets substantially ameliorated EAE 26 , which was consistent with the present study demonstrating that normal (not activated) platelets stimulated Th1/Th17 cells ( Fig. 2 and Fig. 4 ). Here we performed the depletion of platelets during the progression of EAE. We found that depletion of platelets starting from peak of EAE (d20) exacerbated the disease (Fig. 7A ), resulting in an enhanced level of CNS inflammation, as determined by the level of infiltration of macrophages, lymphocytes and CD4 T cells into the CNS (Fig. 7B,C) , and enhanced CD4 T cell proliferation levels in the CNS (Fig.  7D ,E) and periphery ( Fig. 7F ,G) on d35. Similar to our observation for human CD4 T cells (Online Fig.  III ), we found that mouse CD4 T cells that were aggregated with platelets had 18-fold lower level of proliferation and 3.5-fold lower level of IFN- production during EAE (d35) when compared to CD4 T cells that were not aggregated with platelets (Online Fig. VI) . Thus we further demonstrated that platelets play a regulatory role during progression of EAE and most likely during progression of MS.
DISCUSSION
In this article we have demonstrated a dual role for platelets in the stimulation and inhibition of pathogenic CD4 T cells in MS. Normal (not activated), but not in vitro or in vivo activated platelets, produced 5HT upon stimulation and contributed to Th1/Th17 differentiation. In both MS patients and the EAE model, signs of platelet activation/degranulation were observed during the early stages of the disease, whereas the levels of platelet-CD4 T cell aggregates were increased during progression of the disease at more advance stages. Activated platelets had higher capacity to form platelet-CD4 T cell aggregates during disease progression, and adhesion of activated platelets to CD4 T cells decreased T cell activation leading to downmodulation of EAE.
Serotonin is an important neurotransmitter that can directly affect functions of neurons in the CNS and can modulate the functions of the immune cells in the periphery, and thus may play a role in MS epidemiology 47 . In mammals, 5HT is found in the gastrointestinal tract, platelets, and in the CNS 38 . In the peripheral blood, platelets are the exclusive source of serotonin that is stored in platelet granules 3, 8 . It has been reported that elevated levels of 5HT in the cerebrospinal fluid (CSF) correlated with MS progression, and might thus indicate platelet degranulation and secretion of 5HT in the CNS in the areas of inflammatory lesions upon recognition of LR 26 . This was supported by the finding that during EAE and MS other platelet-derived PAF accumulated in the CNS and CSF 48, 49 . These platelet derived soluble factors could promote Th1/Th17 differentiation in the CNS and periphery. During advanced stages of the disease, secretory granules become depleted/exhausted and activated platelets form aggregates with T cells (Online Thus the study suggests that degranulation and subsequent release of several platelet-derived soluble factors contributed to CD4 T cell proliferation and proinflammatory cytokine production, while formation of aggregates with platelets resulted in decrease in T cell proliferation and production of proinflammatory cytokines. Thus depending on the stage of MS or EAE disease, platelets could play proinflammatory and regulatory roles as summarized in Fig. 8 . In early stages of MS platelets have high levels of proinflammatory mediators stored their granules such as 5HT, PAF, PF4, which are released when platelets become activated at the site of CNS inflammation by recognizing brain-specific LR or subendothelial matrix in damaged blood vessels (Fig.8A ). In addition, degranulating platelets could produce a number of mediators that activate endothelial cells and promote migration of CD4 T cells into CNS (Fig. 8A) . Late in MS the granule constituents of activated platelets become depleted, but platelets upregulate CD62P and adhere to activated CD4 T cells leading to their deactivation (Fig. 8B) .
We found in our study that the formation of platelet-CD4 T cell aggregates was mediated at least in part via CD62P on activated platelets and CD166 on activated CD4 T cells. Besides CD166, CD62P on platelets can bind to other molecules on CD4 T cells such as P-selectin glycoprotein ligand-1 42 and TIM-1 50 . In addition, activated platelets express a number of integrins that could also contribute to cell contact interactions of platelets with activated T cells 51 . We believe that binding of platelets to T cells resulted in perturbed interaction of CD4 T cell with antigen presenting cells to cause decrease in T cell activation and migration of T cells to the site of inflammation (Fig. 8B) . In support of our hypothesis it was reported that ALCAM substantially contributed to human and mouse T cell activation and migration of CD4 T cells into CNS in EAE model 52, 53 . In summary, our data indicate a role for platelets in the immunopathogenesis of CNS autoimmune demyelinating disease, which may provide new opportunities for diagnostics and the treatment of MS by monitoring and modulating the functions of platelets. In (A-D, F-G) , mean with individual data points or mean ± S.E. is shown (*, p<0.05; **, p<0.01; ***, p<0.005). Unpaired Student's tests and Mann-Whitney U tests were used to determine statistical significance as described in Methods. In (A-H), mean ± S.E. of 3-5 separate experiments is shown (*, p<0.05; **, p<0.01; ns, not significant). In (A, C-F), mean ± S.E. of 6-8 individual mice is shown (*p<0.05; **, p<0.01). In (B) mean ± S.E. of triplicate is shown. Effectiveness of platelet depletion by i.p. administration of anti-TS was assessed by platelet counts in the peripheral blood as described in Methods. In (B-C), platelet rich plasma was obtained from mouse peripheral blood, and platelets were isolated from platelet rich plasma of normal mice (B, C) or mice with EAE (C) by centrifugation, and the amount of serotonin was determined in platelet lysate as described in Methods. In (B), washed platelets were activated with TB or ADP in vitro as described in Methods and then level of 5HT was analyzed in platelet lysate. Relative levels of 5HT are shown in comparison with unmanupulated mice.
SOURCES OF FUNDING
In (A-D), mean ± S.E. of total 4-10 individual mice for each group is shown for two separate experiments (*, p<0.05; **, p<0.01; ***, p<0.001). In (C), (E) and (G), mean ± S.E. of the group of 5-8 individual animals is shown (*, p<0.05; **, p<0.01; ***, p<0.005).
Figure 8. Model of differential regulation of CNS autoimmune inflammation by platelets during disease initiation and progression. (A)
In the early stages of the neuroinflammation platelets have nonactivated phenotype with a low level of P-selectin (CD62P) expression and a high level of proinflammatory factors stored in platelet's granules. During initial neurovascular damage in the early stages of CNS inflammation, normal platelets degranulate upon interaction with astroglial or neuronal glycolipids (brain lipid rafts), and/or subendothelal matrix, and the constituents of platelet granules PAF, PF4 and 5HT are released. In the CNS and the periphery platelet-derived PAF, PF4 and 5HT increased proliferation and differentiation of CD4 T cells into pathogenic Th1/Th17 cells upon interaction with antigen presenting cells (APCs). In addition, soluble platelet-derived mediators activated endothelial cells and facilitate the migration of CD4 T cells from blood vessels into the CNS. (B) In the late stages of the neuroinflammation platelets exhibited activated phenotype with low levels of platelet granule constituents such as 5HT and high levels of P-selectin (CD62) expression that resulted in adherence of platelets to activated CD4 T cells or APCs both of which express ALCAM. Formation of platelet-CD4 T cell aggregates prevented interaction of CD4 T cells with APCs in the CNS or periphery, leading to T cell deactivation and downmodulation of CNS inflammation. In addition, formation of platelet-CD4 T cell aggregates prevent migration of CD4 T cells into the CNS.
Novelty and Significance
What Is Known?
 Platelets can modulate inflammation by producing proinflammatory factors and interacting with immune cells.
 Platelets become activated during autoimmune diseases such as multiple sclerosis, but the role of these cells in the pathogenesis of autoimmune diseases remains uncertain.
 Although experimental autoimmune encephalitis (EAE) is widely used as a model for multiple sclerosis (MS), not all results obtained in EAE model could be directly translated to MS.
What New Information Does This Article Contribute?
 In early stages of MS and EAE, platelets become activated and produced soluble proinflammatory factors that specifically stimulated the differentiation of CD4 T cells towards pathogenic Th1 and Th17 phenotypes and promoted neuroinflammation.
 At the more advanced stages of neuroinflammation activated platelets became exhausted in their ability to secrete proinflammatory factors, but substantially increased their ability to form aggregates with CD4 T cells, contributing to downmodulation of T cell activation and resolution of inflammation.
 The results obtained with the EAE model are in a very good agreement with the results in patients with MS
It is known that platelets regulate inflammation in many types of pathological conditions; however, the exact mechanism of such regulation remains uncertain. We found that at early stages of central nervous system autoimmune inflammation (also known as neuroinflammation) platelets stimulate adaptive immune response by promoting expansion and differentiation of CD4 T cells towards Th1 and Th17 phenotypes, which play pathogenic role in several types of autoimmune diseases including multiple sclerosis. During resolution of neuroinflammation activated platelets form aggregates with CD4 T cell leading to a decrease in T cell activation, which contributed to recovery from the disease. These results suggest that platelets play an important role in the regulation of adaptive immune response during inflammation, which might be viewed as a general mechanism by which platelets regulate immune responses during inflammatory diseases. Under such pathologic conditions platelets could be considered as "innate-like immune cells" that stimulate or inhibit CD4 T cells during initiation and resolution of inflammation. Hence, investigation of platelet-CD4 T cell interactions may have implications for diagnostics and treatment of several types of pathologic inflammatory conditions associated with neurovascular diseases such as multiple sclerosis, stroke, and atherosclerosis. Contents:
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Subjects
Peripheral blood samples were obtained after receipt of written informed consent from healthy controls and MS patients. The study was approved by the institutional review boards at Brigham and Women's Hospital and at the Chinese University of Hong Kong. MS patients participated as a part of the CLIMB study at Brigham and Women's Hospital (1) and the study at the Chinese University of Hong Kong consisted of a group of untreated relapsing-remitting and secondary progressive MS patients (Supplemental Table I ).
Isolation of lipid rafts
To purify the lipid rafts from the human brain, unidentified frozen autopsy samples from New York tissue bank were used. The work with human autopsy samples was approved by Harvard Medical School review board committee. Brian tissues were separated from meninges the lipid rafts were isolated by the homogenization of the brain tissue in PBS with 0.5% Triton X-100. The homogenate was then centrifuged at low speed (250g) for 5 minutes and the supernatant was filtered through 0.4 µ and nylon filter (Millipore) and washed two times with PBS by the centrifugation at high speed (16,000g, 10 min) as described (2) . The amount of lipid rafts was quantified using a kit for the measurement of the concentration of phospholipids (Wako Chemicals) and used at concentration of 5 µg of phospholipids in 1 ml.
Platelet and mononuclear cell isolation and analysis
For isolation and analysis of human platelets, peripheral blood samples were drawn using 5-10 ml collecting tubes with EDTA (BD Biosciences). Blood samples were kept at room temperature and platelets were analyzed within 2 hours of blood collection.
For the analysis of platelet-CD4 T cell aggregates, whole blood was diluted with PBS (1:10) and analyzed by multicolor flow cytometry after staining with anti-CD42a (human), or anti-CD41 (mouse) and anti-CD4 antibodies similarly as described (3) . The samples were incubated with proper antibodies (dilutions are 1:200 for anti-mouse antibodies and 1:5 for anti-human antibodies) in the total volume of 250-300 µl for 15 min at room temperature and then fixed by addition of 1 ml of 1% paraformaldehyde in PBS. Platelet-CD4 T cell aggregates were analyzed by multicolor flow cytometry and the percentage of aggregates was identified by calculating the fraction of CD4 + CD42a + (human) or CD4 + CD41 + (mouse) double positive aggregates out of all CD4 + cells.
For assessment of Annexin V expression on platelets, platelet rich plasma was gained from peripheral blood by low speed centrifugation at 250g for 5 minutes at room temperature. After which, platelet rich plasma containing 1.5 x 10 6 cells was diluted in Annexin-binding buffer (BS Bioscieces) and 200 µl of platelet rich plasma were incubated with 50 µl of anti-CD42-PerCP antibodies and 3 µl of Annexin V-PE (both from BS Biosciences) for 20 min at room temperature. Then the samples were diluted with 1 ml of Annexin-binding buffer and analyzed by FACS within 30 min.
The analysis of Ca 2+ influx in ex-vivo isolated platelets in response to brain lipid rafts was performed using Fura 2M probe as described in our previous studies (2, 4) . Fura-2M probe, a membrane-permeable derivative of Fura-2, was purchased from Molecular Probes. Platelet rich plasma was diluted with HBSS to proper platelet concentration (10 7 /ml) and platelets were loaded with 1 μM Fura-2M at 37 o C for 30 min. Washed platelet suspensions were then prepared by centrifugation for 10 min at 10,000g and re-suspension of the pellet in HBSS buffer. Fura-2M fluorescence signal measurements at 340 and 380 nm excitation were conducted at room temperature using spectrofluorometer system (TECAN) after addition of lipid rafts (5 µl/well).
For isolation of peripheral blood mononuclear cells (PBMCs) from HC subjects or MS patients, blood samples were drawn from the same group of patients as for the platelet analysis by using 10 ml collecting tubes with heparin (BD Biosciences). PBMCs were isolated using the Ficoll density gradient (Ficoll-Paque Plus from GE Healthcare) according to the standard protocol (2, 3).
Mouse platelets were isolated from the peripheral blood as described previously (2) . To isolate mouse platelets, blood was collected through cardiac puncture (0.38% sodium citrate was used as anticoagulant agent) using 1 ml syringe. Platelet rich plasma was obtained by a low speed centrifugation (250g, 5 min), while platelets were isolated by high speed centrifugation (10,000g, 10 min).
For the assessment of platelets and platelet-derived microparticles by FACS, the forward and size scatter parameters on the flow cytometer were set to a logarithmic scale and the CD61 + CD42a + gated cells in the "platelet" forward/size scatter gate were analyzed as platelets, and the CD42a + particles in the subplatelet "microparticle" forward/size scatter gate were determined as platelet-derived microparticles as described (2).
Human Anti-human CD42a-PerCP, CD4-FITC and PE conjugated Annexin V were purchased form BD Biosciences. Anti-mouse CD4-FITC, CD61-FITC, CD41-PE, CD11b-PE, CD41-PE-Cy7 and CD4-APC antibodies were purchased form BD Biosciences. Anti-mouse CD45-APC-Cy7antibodies were purchased from Biolegend.
Platelet 5HT content and 5HT/PF4 and Release Assays
Serotonin was assessed in platelet lysate or in the supernatant. To assess 5HT in platelet lysate, platelet rich plasma was obtained and platelet numbers were counted. The volume was adjusted to have equal number of platelets in all samples (2x10 8 ) and platelets were centrifuged at 10,000g for 10 min.. Platelet pellet was resuspended in 100 µl of milliQ water and kept at -70°C before analysis. 5HT level was analysed by ELISA according to instructions for Serotonin ELISA kit (Abcam)
To assess 5HT or PF4 in supernatant after stimulation of platelets with brain lipid rafts, 300 µl of the platelet rich plasma were mixed with 60 µl of the brain lipid rafts or PBS and incubated for 30 minutes for serotonin and 1 hour for PF4 assessments at +37°C. Then the samples were centrifuged at 10,000 g for 10 minutes at +4°C and 100 µl supernatant (platelet-free plasma) was used for serotonin (GenWay and Abcam), or mouse PF4 (Uscn Life Science) assessments using ELISA kits according to the manufacturer's recommendations.
Platelet-T cell co-culture
Human CD4 T cells were isolated from PBMCs preparations by negative selection using a magnetic separation kit (BD Biosciences), and stimulated for six days with plate-bound anti-CD3/CD28 antibodies (1 μg/ml; BD Biosciences) in RPMI media with 10% FBS (5) without or with various numbers of syngeneic or allogeneic washed platelets that were obtained from platelet-rich plasma by centrifugation as described previously (2) . Cytokine production in culture supernatants were measured by ELISA similarly as described (5) using kits from BD Biosciences. Syngeneic and allogeneic co-cultures of CD4 T cells with platelets demonstrated similar results (not shown). In several co-culture experiments, anti-PF4 (25 μg/ml, "PeproTech") mAbs and PAF receptor inhibitor WEB2086 (10 -5 M, "Sigma") were used
Mouse CD4 T cells were isolated from the spleen by negative selection using a BD Biosciences kit similarly as for human CD4 T cells and stimulated with soluble or immobilized anti-CD3 (2-4μg/ml for soluble; 10 μg/ml for immobilized; BD Biosciences) with or without soluble anti-CD28 (4μg/ml; BD Biosciences) activating antibodies. Stimulation with soluble anti-CD3 was done in the presence of irradiated syngeneic splenocytes (at the ratio of 1:5) used as antigen presenting cells, with or without TBor ADP-activated and washed mouse autologous platelets (1:20) for three days for analysis of T cell activation markers CD25-PerCP and CD44-APC on CD4 T cells.
TB and ADP were purchased for Sigma. Blocking anti-mouse CD62P antibodies (30 μg/ml) were purchased from BD Biosciences, polyclonal anti-mouse CD166 antibodies (25μg/ml) were purchased from R&D Systems, and rabbit polyclonal anti-serotonin antibodies (1:500) were purchased from GenWay. Before addition to the culture anti-serotonin antibodies or control serum were washed with PBS using Centricon 50kDa membrane filter units (Millipore). Activation of human and mouse platelets with thrombin (TB) or ADP was performed as previously described (2) .
Mouse models C57BL/6 mice were purchased from Jackson Laboratories. B6.MOG-TCR transgenic 2D2 mice were maintained in our colony. All animal protocols were approved by Harvard Medical School and the Chinese University of Hong Kong Institutional Animal Ethics Committees.
For CD4 T cell recall response, MOG-TCR transgenic mice were immunized with 150 µg MOG 35-55 (American peptide) in 4 mg/ml CFA (Diffco) 26 . Platelet depletion was performed similarly as described earlier (2) . On days 0, 2, 4, 6 and 8 post-immunization 30 µl of anti-TS or CS was injected i.p., and on day 10 post-immunization CD4 T cells were analyzed for cytokine expression and proliferation.
For analysis of CD4 T cell apoptosis, ex-vivo isolated stimulated T cells were stained for CD4-FITC and Annexin V-PE, washed with Annexin V binding buffer (BD Bioscieces) and were analysed by threecolor flow cytometry within 30 min in the presence of 7-Aminoactinomycine D (7AAD, BD Biosciences).
For EAE induction, 8-12-week-old B6 mice were immunized with 150 µg MOG in 4 mg/ml CFA with administration of Pertussis toxin (Sigma, 150 ng/mouse) on day 0 and day 2 as described previously (6, 7) . The mice were observed for the signs of disease starting on day five post-transfer, and the disease severity was scored on a numerical scale 0-5 as follows: 0) no disease; 1) weak tail or wobbly walk; 2) hind limb paresis; 3) hind limb paralysis; 4) hind and forelimb paralysis; and 5) death or euthanasia due to humane reasons.
Rabbit anti-mouse thrombocyte polyclonal antibodies (serum; anti-TS) was purchased from Accurate Chemical & Scientific Corp. Anti-CD62P NA/LE grade antibodies were purchased from BD Biosciences For depletion of platelets or blocking of cell contact interactions of activated platelets with CD4 T cells during late stage of EAE, 20-30 µl of anti-TS or 50 µl of anti-CD62P mAb (1 mg/ml), or CS was injected i.p. or i.v. as indicated (2) . Platelets counts were decreased with anti-TS from 5-8 to 0.1-0.3 (×10 5 /µl) as measured 24 hours after i.p injection.
Flow cytometry analysis of expression of intracellular molecules
For intracellular detection of IL-17, IFN-, IL-4, or FoxP3 expression, mouse or human T cells were activated with phorbol myristate acetate (50ng/ml) and ionomycin (1 μg/ml; both from Sigma) in the presence of GolgiStop (1µl/ml, BD Biosciences) for four hours. Cells were immediately stained for surface markers (CD4 only for assessment of CD4 T cells, or CD4 and CD25 for assessment of Tregs, or CD4 and CD42a (human) or CD41 (mouse) for assessment of cytokine expression in CD4 T cells aggregated vs. not aggregated with platelets), fixed/permeabilized and stained for intracellular antigens with proper antibodies directly conjugated with fluorophores. For human surface markers anti-CD4-FITC, CD25-PE, CD42a-PerCP were used (BD Biosciences). For mouse surface marker analysis CD4-FITC, CD4-APC, CD41-PE, CD41-PE-Cy7 monoclonal antibodies were used (BD Biosciences). Antibodies for intracellular cytokine staining analysis (anti-human IL-17-PE, IL-17-AF647, and IFN--APC; anti-mouse IL-17-PE, and IFN--PE) were purchased from BD Biosciences. APC conjugated antibodies for intracellular FoxP3 staining were purchased eBioscences. The data was acquired on LSR II and LSR Fortessa cytometers (BD Biosciences) and was analyzed with FlowJo software (TreeStar Inc.). Isolation of mononuclear cells from the CNS and spleen of mice with EAE and FACS analysis was performed as described previously (6, 8, 9) .
For isolation of mononuclear cells from mouse peripheral blood, blood was collected through cardiac puncture using 1 ml syringe (0.38% sodium citrate was used as anticoagulant). For isolation of mononuclear cells from mouse spleens, splenocytes were isolated by homogenization of whole spleen using 40µ Cell strainer (BD Biosciences). To isolate mononuclear cells from blood or spleen, the cell suspensions were overlayed over 5 ml of Ficoll-Paque Plus (GE Healthcare) and centrifuged at cell culture centrifuge at 2000 rpm for 30 min. To isolate mononuclear cells from the CNS, mice were perfused intracardially with PBS, brains and spinal cords were dissected and homogenized. CNS mononuclear cells were further isolated using 40%/70% Percoll (Sigma) density gradient. Calculation of absolute numbers of the cells in the CNS or periphery was also performed as previously described (2 + CD45 hi macrophages were calculated by multiplying the total cell count obtained using a hemocytometer by the percentage of these cells determined by flow cytometry.
Proliferation assays
BrdU incorporation assay was used to assess proliferation of CD4 T cells in vitro or in vivo as was described in our earlier studies (6) . To perform this analysis we used BrdU kit from BD Biosciences following manufacturer's instructions. BrdU was added to cultures (10 µM) or injected i.p. (2 mg/mouse) 14 hours prior to analysis. For assessment of the level of proliferation of CD4 T cells aggregated vs. not aggregated with platelets, the cells were co-cultured with the same numbers of non-activated/washed or TB-activated/washed platelets for 3 days (human) or isolated ex-vivo (mouse), stained for surface markers CD4 and CD42a (human) or CD41 (mouse), fixed/permeabilized and stained with FITC conjugated antiBrdU antibodies according manufacturer's instructions for BrdU kit. Analysis of T cell proliferation using 3 H-thymidin ( 3 H-Td) incorporation analysis was performed as described (10) . The cells were stimulated with MOG peptide (2-10 µg/ml) and pulsed with 3 H-Td 48 hours later. The cells were analyzed on cell harvester 24 hours after addition of 3 H-Td.
Scanning electron microscopy
Mouse CD4 cells were stimulated with immobilized anti-CD3 antibodies for two days. The alive cells were separated from dead cells using Ficoll gradient, washed with PBS and placed on coverslips pre-coated with anti-CD3 antibodies and co-cultured with syngenic washed platelets (ratio 1:15) for eight hours. After that the cells on coverslips were rinsed with 0.1M Sorensen' phosphate buffer (PB, pH=7.2), fixed with 2.5% glutaraldehyde in PB for 1hour at room temperature. Fixed specimens were washed with PB three times for 10 min for each wash and further fixed with 2% osmium tetroxide for 1 hour. Then the cells were washed three times in milliQ water (10 min each wash). The samples were then dehydrated in graded ethyl alcohols (EtOH): 70-75%, 80-85%, 90-95% (15 minutes for each step), then dehydrated in 95% EtOH and in absolute EtOH (2 changes, 15 min each step) and placed in LADD Critical Point Dryer. Finally the samples were mounted on specimen stubs and coated with gold-palladium on Edwards Sputter Coater right before examination under the Hitachi SU8010 Scanning Microscope.
Statistical Analysis
The results are presented as mean and individual data-point, mean ± S.E., or mean (S.D.). Unpaired Student's t-test and Mann-Whitney U test were used to determine significance between groups. P values of less than 0.05 were considered significant. When appropriate the Mann-Whitney U test was used in addition to Unpaired Student's t-test to further confirm the significance between groups with semi-normal distributions (e.g. Fig. 1A ). Prism GraphPad and SigmaPlot software were used for creating graphs and performing statistical analysis. Result Description: It was demonstrated that 5HT contributed to the activation of CD4 T cells and stimulated the proliferation and the production of IFN- by CD4 T cells (11, 12) . Therefore we proposed that platelet-derived serotonin promoted the proliferation and differentiation of human CD4 T cells towards pathogenic phenotypes. To test this hypothesis we added anti-5HT polyclonal antibodies (serum) or control serum (CS) to our co-cultures and found that anti-5HT serum partially abrogated platelet-induced proliferation and differentiation of CD4 T cells towards Th1 as indicated by BrdU incorporation assay and IFN- production (Supplemental Fig. IIA,B ; see the Legend below).
Supplemental
However, anti-5HT serum did not affect IL-17 production (not shown) indicating that other factors contributed to Th17 differentiation. It was reported that other platelet-derived soluble factors such as PF4 and PAF could also contribute to Th17 differentiation (13) (14) (15) (16) . By using anti-PF4 antibodies and PAF receptor inhibitor, we found that both PF4 and PAF contributed to Th17 differentiation during co-culture of platelets with CD4 T cells (Supplemental Fig. IIC) .
Thus platelet-derived 5HT contributed to increased proliferation of CD4 T cells and differentiation towards Th1, while PF4 and PAF contributed to Th17 differentiation. Result Description: It was reported that CD62P, which is expressed on activated platelets, played an important role in the formation of platelet-leukocyte aggregates including CD4 T cells in humans and mice (17) (18) (19) . Indeed we found that the addition of activated platelets to activated mouse CD4 T cells resulted in relatively high levels of platelet-CD4 T cell aggregates (Supplemental Fig. IVA,B ; see the Legend next page). At the same time, binding of activated platelets to CD4 T cells was decreased 2-fold after the addition of blocking anti-CD62P antibodies to co-cultures of platelets with CD4 T cells (Supplemental Fig. IVA,B) . We have previously shown that CD62P can directly bind to ALCAM in vitro (2) . ALCAM (CD166) is an adhesion molecule that is expressed on activated CD4 T cells, APCs, activated endothelial cells and plays an important role in CD4 T cell activation and EAE pathogenesis (20, 21) . We found that the addition of blocking anti-CD166 antibodies to co-cultures of platelets with CD4 T cells resulted in ~2-fold decrease in the percentages of platelet-CD4 T cell aggregates (Supplemental Fig. IVA,B) . It was reported that ALCAM on APCs provides a co-stimulatory signal to T cells by interacting with ALCAM ligands such as CD6 and other ALCAM molecules expressed on T cells (20, 22) (Supplemental Fig.   IVC ). CD6 gene polymorphism was also shown to be associated with high susceptibility to MS (23) . We hypothesized that activated platelets, which express high levels of CD62P, bind to ALCAM on APCs and activated CD4 T cells and block co-stimulatory signals for CD4 T cells. It was previously reported that ALCAM-CD6 interactions significantly contributed to co-stimulation of CD4 T cells and expression of T cell activation markers (22) . To test this we activated mouse CD4 T cells through TCR using soluble activating anti-CD3 mAbs in the presence of antigen presenting cells that provided co-stimulatory signals to CD4 T cells through ALCAM-CD6 and ALCAM-ALCAM interactions (Supplemental Fig. IVC) . We found that in this system the addition of blocking anti-CD166 antibodies or activated platelets significantly decreased expression of activation markers CD25 and CD44 on CD4 T cells (Supplemental Fig. IVD,E) .
However in the presence of soluble anti-CD28 antibodies that provide a co-stimulatory signal in addition to antigen presenting cells (Supplemental Fig. IVC) , activated platelets in co-cultures did not cause the decrease in expression of CD25 and CD44 on CD4 T cells (Supplemental Fig. IVD,E) . Thus we proposed that activated platelets have a high capacity to bind CD4 T cells and APCs via CD62P-ALCAM interactions and interfere with the delivery of co-stimulatory signals from antigen presenting cells to T cells leading to a decreased level of CD4 T cell activation. One representative experiment is shown in (D), mean ± S.E. of 3-4 separate experiments is shown for relative MFI levels (percentages of the controls) is shown in (E).
Supplemental Figure V. Visualization of interactions of CD4 T cells with platelets.
Mouse CD4 T cells were stimulated with anti-CD3 antibodies in the presence of platelets and analyzed by scanning electron microscopy as described in Supplemental Methods. Interactions of platelets of activated morphology (marked with red pseudocolor) with CD4 T cells (marked with blue pseudocolor) were observed as a formation of platelet-CD4 T cell aggregates (A) and paracrine interaction of clustered activated platelets with CD4 T cells without obvious platelet-CD4 T cell aggregate formation (B). Plateletderived microparticles were also evident and marked with pink pseudocolor (size of the bar is 5 µ; X 10,000 (A) and X 9,000 (B) magnifications). Representative images are shown.
Supplemental Figure VI. Influence of CD4-platelet aggregate formation on proliferation and Th1 differentiation of mouse CD4 T cells in vivo.
On day 35 after EAE induction, mononuclear cells were isolated from spleen using Ficoll gradient and CD4 T cells that were aggregated with platelets (CD4 + CD41 + subset) vs. not aggregated with platelets (CD4 + CD41 -subset) were analyzed similarly as described in Supplemental Methods. For BrdU analysis, BrdU was injected i.p. 14 hours prior to isolation of splenocytes (see Supplemental Methods). For IFN- analysis, ex-vivo isolated splenocytes were activated with phorbol myristate acetate and ionomycin as described in Supplemental Methods. Representative contour-plot of four individual mice is shown.
